The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Six-months follow-up of prevention trial showed 83% reduced risk of symptomatic Covid-19, with no severe disease or deaths
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Viyash has ten manufacturing facilities in India with a combined capacity of 2000 KL as well as one formulation facility in the US, and is now one of India’s leading mid-tier integrated API and formulation players
If approved or authorized, Paxlovid would be the first oral antiviral of its kind, to combat SARS-CoV-2
It is India’s first pneumotach based portable wireless Spirometer for diagnosis of Chronic Obstructive Pulmonary Disorder (COPD)
Two out of three people under the age of 40 are at risk of prediabetes
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
Forty-two per cent Indian patients with Coronary Artery Disease (CAD) or Peripheral Artery Disease (PAD) described “confusion about what I was supposed to do next” as an important barrier to early and accurate diagnosis
The company performed particularly well in operational eco-efficiency, environmental and social reporting
Subscribe To Our Newsletter & Stay Updated
